The news that Alzamend Neuro's lithium dose is designed to not require therapeutic drug monitoring is positive for the company. This feature could make the product more attractive to patients and healthcare providers, as it simplifies the treatment process and reduces the burden of monitoring. This could potentially lead to increased adoption of the product and, in turn, have a positive impact on the company's stock price in the short term.